Focused On-demand Library for Glucose-dependent insulinotropic receptor

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.

Fig. 1. The sreening workflow of Receptor.AI

It includes extensive molecular simulations of the receptor in its native membrane environment and the ensemble virtual screening accounting for its conformational mobility. In the case of dimeric or oligomeric receptors, the whole functional complex is modelled, and the tentative binding pockets are determined on and between the subunits to cover the whole spectrum of possible mechanisms of action.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q8TDV5

UPID:

GP119_HUMAN

Alternative names:

G-protein coupled receptor 119

Alternative UPACC:

Q8TDV5; Q495H7; Q4VBN3

Background:

The Glucose-dependent insulinotropic receptor, also known as G-protein coupled receptor 119, plays a pivotal role in metabolic regulation. It serves as a receptor for oleoylethanolamide and lysophosphatidylcholine, substances involved in energy homeostasis and glucose metabolism. Activation of this receptor by its ligands triggers a cascade of events through G proteins, predominantly via a G(s) mediated pathway, leading to the stimulation of adenylate cyclase.

Therapeutic significance:

Understanding the role of the Glucose-dependent insulinotropic receptor could open doors to potential therapeutic strategies. Its involvement in glucose-dependent insulin release positions it as a promising target for the development of treatments for metabolic disorders, including diabetes.